(secondQuint)Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma.

 This is a two-part study; each part of the study (Part 1 and Part 2) will be approximately 34 weeks in duration including a 4-week screening phase, a 24-week placebo-controlled treatment phase and a six-week follow-up phase.

 In Part 1, patients will be randomly assigned to receive placebo or JNJ-39758979 300 mg once daily through Week 24.

 In Part 2, patients will be randomly assigned to 1 of 4 treatment groups to receive treatment with placebo, 30 mg, 100 mg, or 300 mg of JNJ-39758979 once daily through Week 24.

 Safety assessments and evaluations to determine the efficacy of JNJ-39758979 to reduce the signs and symptoms of asthma will be performed both on a daily basis via electronic diary and at study visits.

.

 Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma@highlight

The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting beta 2-agonist (LABA) and/or montelukast for at least 4 weeks.

